guest ::
| Home > Publications database > Effect of degeneration stage on non-viral tissue transfection of rd10 retina ex vivo > print |
| Home > Publications database > Effect of degeneration stage on non-viral tissue transfection of rd10 retina ex vivo > print |
| 001 | 1044403 | ||
| 005 | 20260123203311.0 | ||
| 024 | 7 | _ | |a 10.1016/j.omtn.2025.102616 |2 doi |
| 024 | 7 | _ | |a 10.34734/FZJ-2025-03167 |2 datacite_doi |
| 037 | _ | _ | |a FZJ-2025-03167 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Zhang, Jiao |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Effect of degeneration stage on non-viral tissue transfection of rd10 retina ex vivo |
| 260 | _ | _ | |a New York, NY |c 2025 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1769162618_14858 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a This work was supported by the Confocal Microscope Facility and the Immunohistochemistry Facility, core facilities of the Interdisciplinary Center for Clinical Research (IZKF) Aachen within the Faculty of Medicine at RWTH Aachen University. Thethors thank Anne Freialdenhoven, Antje Schiefer, and Alicia Hühnlein (Department of Ophthalmology, University Hospital RWTH Aachen) for excellent technicaltance. This work was funded by the China Scholarship Council (no. 202208080251) and is part of a graduate school funded by the Deutsche Forschungsgemeinschaft DFG under GRK 2610/01. The results shown here are part of the doctoral thesis of J.Z. |
| 520 | _ | _ | |a Gene therapy has great potential for the treatment of inherited retinal diseases, as evidenced by the progress and ongoing research. Using the Sleeping Beauty (SB) transposon system, we developed a non-viral gene delivery system for electroporation-based transfection of rd10 retinas ex vivo. SB100X transposase and Venus transposon plasmids were transfected at a ratio of 1:16 into rd10 retinas of different ages and corresponding wild-type (WT) controls. Transfection efficiency was assessed by fluorescence microscopy and transfected cells were identified by immunohistochemistry. Retinal integrity and cell viability were assessed by FITC-dextran electroporation, histology, and apoptosis assay. The highest transfection efficiency was observed in degenerated stages P61 and older, with Müller cells being the only transfected cell type. A 31% reduction in transposon plasmid size resulted in a 1.5-fold increase in transfection efficiency. Integrity and morphology of degenerated retinas were preserved after electroporation-based plasmid transfer; the number of apoptotic cells in the inner nuclear layer (INL) was reduced by half compared to WT controls. We demonstrated that electroporation-based delivery of the SB transposon system resulted in efficient transfection of degenerated retinas. Our results are an important first step toward the combined use of retinal prostheses and gene therapy to improve the treatment of inherited retinal dystrophies. |
| 536 | _ | _ | |a 5244 - Information Processing in Neuronal Networks (POF4-524) |0 G:(DE-HGF)POF4-5244 |c POF4-524 |f POF IV |x 0 |
| 536 | _ | _ | |a GRK 2610 - GRK 2610: Innovative Schnittstellen zur Retina für optimiertes künstliches Sehen - InnoRetVision (424556709) |0 G:(GEPRIS)424556709 |c 424556709 |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Bing, Ziyu |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Marie, Corinne |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Izsvák, Zsuzsanna |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Müller, Frank |0 P:(DE-Juel1)131939 |b 4 |
| 700 | 1 | _ | |a Thumann, Gabriele |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Walter, Peter |0 P:(DE-Juel1)209653 |b 6 |u fzj |
| 700 | 1 | _ | |a Johnen, Sandra |0 P:(DE-HGF)0 |b 7 |e Corresponding author |
| 773 | _ | _ | |a 10.1016/j.omtn.2025.102616 |g Vol. 36, no. 3, p. 102616 - |0 PERI:(DE-600)2662631-7 |n 3 |p 102616 - |t Molecular therapy / Nucleic Acids |v 36 |y 2025 |x 2162-2531 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1044403/files/Molecular_Therapy_M%C3%BCller_06_2025.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:1044403 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131939 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)209653 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-524 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Molecular and Cellular Information Processing |9 G:(DE-HGF)POF4-5244 |x 0 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-05 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL THER-NUCL ACIDS : 2022 |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T08:49:38Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T08:49:38Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-05 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-05 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T08:49:38Z |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-05 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOL THER-NUCL ACIDS : 2022 |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-05 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)IBI-1-20200312 |k IBI-1 |l Molekular- und Zellphysiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INW-1-20231219 |k INW-1 |l Katalytische Grenzflächen |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)IBI-1-20200312 |
| 980 | _ | _ | |a I:(DE-Juel1)INW-1-20231219 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|